Respiratory syncytial virus occurs each year during fall, winter and spring and can be deadly for older people. Pfizer said it plans to seek FDA approval for the new shot soon.
. It usually causes mild, cold-like symptoms in adults but can sometimes lead to life-threatening illness.
Synagis, a monoclonal antibody injection, has been approved for use in the U.S. to prevent severe illness, but it’s only available for certain high-risk infants, like babies who were born prematurely or have a low birth weight. The company said it plans to submit a vaccine application to the Food and Drug Administration for full approval in adults ages 60 and older later this fall.
The company is still gathering data to see how long protection from the initial RSV vaccine lasts, he said, but it is possible it could become an annual immunization like the flu shot.He said the company is also looking to expand testing the vaccine in other age groups, pending discussion and clearance from federal regulators.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer-BioNTech submits new COVID vaccine booster targeting BA.5 to the FDA for authorizationPfizer and German partner BioNTech have submitted their new COVID-19 booster – that targets the omicron subvariant BA.5 – to the FDA for emergency use authorization.
Baca lebih lajut »
Pfizer COVID shots appear 73% effective in children under 5Only about 6% of youngsters ages 6 months through 4 years had gotten at least one dose of a COVID-19 vaccine.
Baca lebih lajut »
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Baca lebih lajut »
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Baca lebih lajut »
Pfizer COVID shots appear 73% effective in children under 5Only about 6% of youngsters ages 6 months through 4 years had gotten at least one dose of a COVID-19 vaccine.
Baca lebih lajut »